Facilitating access and disease treatment with faster to market solutions for respiratory viral infections

Rivanima Therapeutics offers accessible, safe, and lower-cost outpatient treatment options as a priority in our global efforts to combat COVID-19

Reduction in viral load

Diminished risk of advanced disease

Reduced hospitalization

Short and Ambulatory treatment

Accessible

Reduction in viral load

Reduced hospitalization

Accessible

Diminished risk of advanced disease

Short and Ambulatory treatment

ABOUT US

Company Highlights

=

Early-stage Biotech Company, incorporated in DE, USA

=

Operations based in FL, USA and Bogota, Colombia

=

Developing an early and affordable treatment for COVID-19

Janeth Mora

Janeth Mora

CEO

PharmD

Dr. Carlos Riveros

Dr. Carlos Riveros

Founder - CMO

MD

Carlos R. Olarte

Carlos R. Olarte

CIPO

B.S.E, J.D.

Juan D. Martinez

Juan D. Martinez

Growth & Business Development

J.D.

Founders and management team: +50 years Healthcare/Pharma experience

Sizable billions dollars Market (2022) in COVID-19 for early treatment only

Potential for use as Preventative treatment

Opportunity for usage in other diseases

Rivanima Therapeutics

Early-stage, privately owned Biotech Company

Bringing affordable therapeutic solutions to COVID-19 & developing a portfolio of solutions to address other viral diseases

Our Product

Nebuliv

by Rivanima Therapeutics

Has shown efficacy to reduce viral replication in vitro

However, systemic (oral) delivery of Nebuliv is insufficient to reach required concentrations, and reason why this molecule has not shown adequate efficacy in vivo